Clinical Trial Detail

NCT ID NCT02043665
Title Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Viralytics
Indications

urinary bladder cancer

lung non-small cell carcinoma

melanoma

prostate cancer

Therapies

Coxsackievirus A21

Age Groups: senior adult

No variant requirements are available.